Based on the primary PFS analysis of EMBER-3, the FDA approved single-agent imlunestrant in September 2025 for the treatment of patients with ER+/HER2– ESR1 m advanced breast cancer with disease ...

More than one-third of U.S. adults diagnosed with metastatic HER2-negative breast cancer in 2023 did not undergo testing for BRCA mutations, according to a retrospective analysis.Less than half ...

The trial results support Tukysa-Herceptin-Perjeta as yet another option for breast cancer patients in the frontline ...

Is omission of the sentinel lymph node biopsy safe in early breast cancer in patients treated with breast conserving therapy ...

Sound more like science fiction than actual science? Then, brace yourself because there are, at least, 15 breast cancer ...

Eli Lilly and Co shared updated results of Inluriyo (imlunestrant) from a Phase 3 study in previously treated breast cancer patients.

In another first, Sandoz launched in November 2025 the first FDA-approved biosimilar of Tysabri (natalizumab). Tyruko (natalizumab-sztn) is used to treat adult patients with relapsing multiple ...

The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.

Curious how elderberry supplements affects blood sugar and the immune system? Learn what current research shows—plus safety ...

Patients with HER2-positive, hormone receptor (HR)-positive metastatic breast cancer can be safely treated without chemotherapy.

In a Phase 1 trial, women responded well to the novel vaccine. More research is needed to determine whether it can stop the ...

Preoperative breast MRI did not improve LRR, DRFR, or OS outcomes in early-stage breast cancer patients. The trial involved ...